GlassScriptPhysician profile
Steve Sannyoon Kim
NPI 1548213796
$7,680.29
in general payments reported to CMS, 2019-2025
50 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $848 · 2021: $1,308 · 2022: $667 · 2023: $818 · 2024: $1,532 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,131.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,277.82 | 2019-2025 | |
| Amgen INC. | $787.24 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $421.65 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $371.23 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $366.26 | 2019-2022 | |
| Abbott Laboratories | $335.12 | 2020-2025 | Mitraclip, Aveir |
| Abiomed | $327.97 | 2021-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.61 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $296.75 | 2019-2025 | Farxiga |
| Pfizer INC. | $257.38 | 2019-2025 | |
| Novo Nordisk INC | $253.77 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Philips North America LLC | $199.01 | 2023-2025 | Mcot, (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $189.39 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $184.03 | 2019-2022 | |
| Medtronic, INC. | $170.73 | 2021-2024 | Corevalve Evolut R |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $165.29 | 2019-2024 | Veltassa |
| Actelion Pharmaceuticals US, INC. | $158.33 | 2025 | Opsumit, Uptravi |
| Endologix LLC | $150.00 | 2025 | Torus Stent Graft System, Endocross Device |
| Boston Scientific Corporation | $148.99 | 2022-2024 | Watchman Flx |
| Heartflow, INC. | $109.21 | 2023-2025 | Ffrct |
| Lundbeck LLC | $105.81 | 2020-2021 | |
| Esperion Therapeutics, INC. | $93.67 | 2021-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $85.18 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $78.44 | 2021-2025 | Amvuttra, Onpattro |
| W. L. Gore & Associates, INC. | $74.37 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $58.86 | 2021-2023 | Evkeeza |
| Penumbra, INC. | $58.29 | 2025 | Indigo System |
| Arbor Pharmaceuticals, INC. | $51.28 | 2020-2021 | |
| Gilead Sciences, INC. | $51.18 | 2019 | |
| Impulse Dynamics (USA) INC. | $49.80 | 2024 | Optimizer |
| Cvrx, INC. | $49.53 | 2022-2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $44.63 | 2024 | Arcalyst |
| Lilly USA, LLC | $41.44 | 2025 | Zepbound |
| Aroa Biosurgery Incorporated | $37.44 | 2019-2022 | |
| Irhythm Technologies, INC. | $34.08 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $31.91 | 2023 | Inpefa |
| Atricure, INC. | $27.34 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $26.14 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $20.85 | 2025 | Inspire |
| Bridgebio Pharma, INC. | $18.85 | 2025 | Attruby |
| Cardinal Health 200 LLC | $18.75 | 2019 | |
| Ionis Pharmaceuticals, INC. | $18.40 | 2025 | Tryngolza |
| Daiichi Sankyo INC. | $16.57 | 2024 | Injectafer |
| Vivaquant INC, Dba Rhythm Express | $16.45 | 2025 | Rhythm Express |
| Sandoz INC. | $16.04 | 2025 | Treprostinil |
| Shockwave Medical, INC | $15.59 | 2021 | |
| United Therapeutics Corporation | $14.70 | 2023 | Tyvaso |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2020 | |
| Angiodynamics, INC. | $13.52 | 2023 | Venacure 1470 Pro |
| Medicure Pharma INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.